RxDoctor Payments Data

Susan Marshall, MD

Nephrology · New York, NYNPI 1073672515

Payments from drug & device makers

$5,222in general payments, 2019–2025

Across 145 payments — averaging $36.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Janssen Products, LP$563
  • Novo Nordisk$254
  • Boehringer Ingelheim$243
  • Bayer$147
  • plus $496 from 10 others

What the payments were for

  • Food & beverage$4,99596%
  • Education$2264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,222 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$5,370
Medicare patients
24
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$58,914
DovatoDolutegravir Sodium/Lamivudine16$49,164
JardianceEmpagliflozin55$36,342
EliquisApixaban64$34,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,624
LokelmaSodium Zirconium Cyclosilicate12$6,112
Tamsulosin Hcl122$5,424
Atorvastatin Calcium106$3,318
Finasteride57$1,666
Rosuvastatin Calcium27$1,555
Febuxostat11$1,452
Bupropion XlBupropion Hcl28$1,155
Metoprolol Succinate63$1,061
Colchicine18$1,036
Donepezil Hcl17$971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$79$58,91448 claims
Viiv Healthcare CompanyDovato$2,477$49,16416 claims
Boehringer IngelheimJardiance$243$36,34255 claims
GSKTrelegy Ellipta$29$18,62428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 nephrology providers in New York.

Other nephrology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →